biotechman, in case someone takes to heart and believes what you say, the record needs to be aired about your hero Evan. Under his watch, ANX, now name changed to MSTX (and note he was booted out of ANX), spiked to $123.75 a share in 2006 and is now trading, post reverse splits, at .47. That's equivalent of Evan overseeing a fall form $247.50 a share all the way down to $1. If I remember correctly, you were an initial cheerleader of Evan who evolved into a bitter critic of him at the horrible end of his stewardship. How can you be pumping him as a responsible CEO after what happened with Adventrx? Good luck to you and Evan this time around, but please stick to the truth, even if it's disquieting. You wouldn't want to mislead prospective investors, would you?